Business Context and Reporting Period
Company: Black Hawk Acquisition Corporation (BKHA)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended February 28, 2026
Business Overview: Black Hawk is a Cayman Islands-based special purpose acquisition company (SPAC) formed to effect a business combination. As of the reporting date, the Company had not commenced operations and generated no operating revenue. It is currently pursuing a proposed business combination with Vesicor Therapeutics, Inc., valued at a pre-money equity value of $70 million.
Key Financial Metrics
| Metric | Q1 2026 (Three Months Ended Feb 28) | Q1 2025 (Three Months Ended Feb 28) |
|---|---|---|
| Net Income | $139,805 | $658,379 |
| Operating Expenses | $54,189 | $108,769 |
| Interest Income (Trust Account) | $213,442 | $765,911 |
| Interest Expense | ($19,449) | $0 |
| Cash and Cash Equivalents | $178,407 | $101,528 |
| Investments in Trust Account | $24,640,591 | $23,827,149 |
| Working Capital Deficit | ($2,105,080) | Filing text does not provide clear value |
| Total Liabilities | $4,701,432 | Filing text does not provide clear value |
| Shares Outstanding (Public) | 2,124,077 | 6,900,000 |
Material Changes vs. Prior Period
- Significant Share Redemptions: Following an Extraordinary General Meeting in July 2025, approximately 4.78 million public shares were redeemed, reducing the public share count from 6.9 million to 2.12 million. This reduced the Trust Account balance from approximately $23.8 million to $22.7 million at the time of redemption, though interest income has since increased the balance to $24.6 million.
- Net Income Decline: Net income decreased by approximately 79% compared to the prior year quarter, primarily due to a significant drop in interest income earned on the Trust Account ($213k vs $766k) as the principal balance was reduced by redemptions.
- Increased Debt Obligations: The Company incurred new debt obligations, including a convertible note to a related party with an outstanding balance of $997,366 (up from $595,369) and accrued interest expenses of $32,906.
- Target Company Contributions: The target company, Vesicor, contributed $440,988 to cover extension payments and merger costs, recorded as a liability "Due to target company."
Outlook, Risks, and Management Commentary
- Business Combination Status: The proposed merger with Vesicor Therapeutics is pending. The transaction requires regulatory approvals, shareholder votes, and Nasdaq listing approval. The Company filed Amendment No. 3 to its Form S-4 on March 4, 2026.
- Extension of Deadline: Shareholders approved an extension of the business combination deadline to December 22, 2026. The Company may extend the deadline monthly by depositing $150,000 into the Trust Account. Management states it is current on these payments.
- Going Concern Uncertainty: Management has determined that substantial doubt exists regarding the Company's ability to continue as a going concern due to a working capital deficit and the uncertainty of completing the business combination within the required timeframe.
- Nasdaq Compliance Risk: On March 31, 2026, the Company received a notice from Nasdaq stating its Market Value of Listed Securities (MVLS) fell below the $50 million minimum requirement. The Company has 180 days (until September 28, 2026) to regain compliance or face potential delisting.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of February 28, 2026.
Investor Verification Checklist
- Verify the status of the Form S-4 Amendment No. 3 and the timeline for shareholder votes on the Vesicor merger.
- Confirm the Company's plan to regain Nasdaq compliance regarding the $50 million Market Value of Listed Securities requirement.
- Assess the sufficiency of the $178,407 cash balance to cover operating expenses and extension payments until the merger closes or liquidation occurs.
- Review the terms of the convertible notes issued to the Sponsor, specifically the conversion price of $1.00 per share and potential dilution.
- Monitor the effectiveness of internal controls over financial reporting given the management's conclusion of ineffectiveness.